NUCLEOTIDE ANALOGS

• US 20180015095A1
• Filed: 09/28/2017
• Published: 01/18/2018
• Est. Priority Date: 09/15/2014
• Status: Active Grant

• Current Assignee: US Department of Veterans Affairs (Government of the United States of America), Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Hostetler, Karl Y., Beadle, James R., Valiaeva, Nadejda
• Granted Patent: US 10,213,430 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 8/24 Phosphorous; Compounds thereof
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
• CPC Class Codes: C07F 9/657181 the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
• CPC Class Codes: C07F 9/65742 non-condensed with carbocyclic rings or heterocyclic rings or ring systems
• CPC Class Codes: C07F 9/65744 condensed with carbocyclic or heterocyclic rings or ring systems
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Claims

1. A compound of Formula (I):

2. The compound of claim 1, wherein R³ is methyl.

3. The compound of claim 1, wherein Z¹ is oxygen and Z² is oxygen.

4. The compound of claim 1, wherein Z¹ is oxygen;

Z² is NR^Z; and

R^Z is hydrogen.

5. The compound of claim 1, wherein R¹ is —

(CHR⁴)_a—

O—

C_1-24alkyl;

R⁴ is hydrogen; and

a is 2.

6. The compound of claim 1, wherein R² is aryl.

7. The compound of claim 6, wherein R² is phenyl or benzyl.

8. The compound of claim 1, wherein

R¹ is

9. The compound of claim 2, wherein Z¹ is oxygen and Z² is oxygen.

10. The compound of claim 9, wherein R¹ is —

(CHR⁴)_a—

O—

C_1-24alkyl;

R⁴ is hydrogen; and

a is 2.

11. The compound of claim 10, wherein R² is benzyl or phenyl.

12. The compound of claim 2, wherein Z¹ is oxygen;

Z² is NR^Z; and

R^Z is hydrogen.

13. The compound of claim 12, wherein

R¹ is

14. The compound of claim 13, wherein R² is benzyl or phenyl.

15. The compound of claim 1 having the structure:

16. The compound of claim 1 having the structure:

17. A pharmaceutical composition comprising the compound of claim 1, optionally in a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising the compound of claim 2, optionally in a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the compound of claim 5, optionally in a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the compound of claim 8, optionally in a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising the compound of claim 10, optionally in a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the compound of claim 13, optionally in a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising the compound of claim 15, optionally in a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising the compound of claim 16, optionally in a pharmaceutically acceptable carrier.

25. A compound of the structure:

26. A pharmaceutical composition comprising the compound of claim 25, optionally in a pharmaceutically acceptable carrier.